209 related articles for article (PubMed ID: 19090012)
1. Phase 1 and pharmacokinetic study of concurrent carboplatin and irinotecan in subjects aged 1 to 21 years with refractory solid tumors.
Levy AS; Meyers PA; Wexler LH; Jakacki R; Angiolillo A; Ringuette SN; Cohen MB; Gorlick R
Cancer; 2009 Jan; 115(1):207-16. PubMed ID: 19090012
[TBL] [Abstract][Full Text] [Related]
2. Phase I. Trial of irinotecan plus carboplatin in two dose schedules.
Jones SF; Burris HA; Hainsworth JD; Yardley DA; Raefsky EA; Miranda FT; Kuzur ME; Willcutt NT; White MB; Greco FA
Oncology (Williston Park); 2003 May; 17(5 Suppl 5):36-40. PubMed ID: 12800605
[TBL] [Abstract][Full Text] [Related]
3. Population-based maximum tolerated dose of irinotecan and carboplatin.
Wild CA; Wang SE; Gandara DR; Lara PN; Meyers FJ; Tanaka M; Houston J; Lauder J; Lau DH
Oncology (Williston Park); 2003 Jul; 17(7 Suppl 7):11-6. PubMed ID: 12886868
[TBL] [Abstract][Full Text] [Related]
4. Phase I study of induction chemotherapy and concomitant chemoradiotherapy with irinotecan, carboplatin, and paclitaxel for stage III non-small cell lung cancer.
Choong NW; Vokes EE; Haraf DJ; Tothy PK; Ferguson MK; Kasza K; Rudin CM; Hoffman PC; Krauss SA; Szeto L; Mauer AM
J Thorac Oncol; 2008 Jan; 3(1):59-67. PubMed ID: 18166842
[TBL] [Abstract][Full Text] [Related]
5. A phase I study and pharmacologic evaluation of irinotecan and carboplatin for patients with advanced ovarian carcinoma who previously received platinum-containing chemotherapy.
Yonemori K; Katsumata N; Yamamoto N; Kasamatsu T; Yamada T; Tsunematsu R; Fujiwara Y
Cancer; 2005 Sep; 104(6):1204-12. PubMed ID: 16047343
[TBL] [Abstract][Full Text] [Related]
6. A phase I clinical and pharmacologic study of a carboplatin and irinotecan regimen combined with recombinant human granulocyte-colony stimulating factor in the treatment of patients with advanced nonsmall cell lung carcinoma.
Okamoto H; Nagatomo A; Kunitoh H; Kunikane H; Watanabe K
Cancer; 1998 Jun; 82(11):2166-72. PubMed ID: 9610696
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of the combination of topotecan and irinotecan in children with refractory solid tumors.
Rodriguez-Galindo C; Crews KR; Stewart CF; Furman W; Panetta JC; Daw NC; Cain A; Tan M; Houghton PH; Santana VM
Cancer Chemother Pharmacol; 2006 Jan; 57(1):15-24. PubMed ID: 16001174
[TBL] [Abstract][Full Text] [Related]
8. A phase I study of irinotecan as a 3-week schedule in children with refractory or recurrent solid tumors.
Vassal G; Doz F; Frappaz D; Imadalou K; Sicard E; Santos A; O'Quigley J; Germa C; Risse ML; Mignard D; Pein F
J Clin Oncol; 2003 Oct; 21(20):3844-52. PubMed ID: 14551303
[TBL] [Abstract][Full Text] [Related]
9. Phase I and pharmacokinetic study of oral irinotecan given once daily for 5 days every 3 weeks in combination with capecitabine in patients with solid tumors.
Soepenberg O; Dumez H; Verweij J; Semiond D; deJonge MJ; Eskens FA; ter Steeg J; Selleslach J; Assadourian S; Sanderink GJ; Sparreboom A; van Oosterom AT
J Clin Oncol; 2005 Feb; 23(4):889-98. PubMed ID: 15681535
[TBL] [Abstract][Full Text] [Related]
10. Phase I study of irinotecan combined with carboplatin in previously untreated solid cancers.
Fukuda M; Oka M; Soda H; Terashi K; Kawabata S; Nakatomi K; Takatani H; Tsurutani J; Tsukamoto K; Noguchi Y; Fukuda M; Kinoshita A; Kohno S
Clin Cancer Res; 1999 Dec; 5(12):3963-9. PubMed ID: 10632326
[TBL] [Abstract][Full Text] [Related]
11. Extended phase I evaluation of vincristine, irinotecan, temozolomide, and antibiotic in children with refractory solid tumors.
McNall-Knapp RY; Williams CN; Reeves EN; Heideman RL; Meyer WH
Pediatr Blood Cancer; 2010 Jul; 54(7):909-15. PubMed ID: 20405511
[TBL] [Abstract][Full Text] [Related]
12. Phase I clinical and pharmacologic study of weekly cisplatin and irinotecan combined with amifostine for refractory solid tumors.
Souid AK; Dubowy RL; Blaney SM; Hershon L; Sullivan J; McLeod WD; Bernstein ML
Clin Cancer Res; 2003 Feb; 9(2):703-10. PubMed ID: 12576438
[TBL] [Abstract][Full Text] [Related]
13. A phase I study of irinotecan in pediatric patients: a pediatric oncology group study.
Blaney S; Berg SL; Pratt C; Weitman S; Sullivan J; Luchtman-Jones L; Bernstein M
Clin Cancer Res; 2001 Jan; 7(1):32-7. PubMed ID: 11205914
[TBL] [Abstract][Full Text] [Related]
14. Phase I/II and pharmacologic study of irinotecan and carboplatin for patients with lung cancer.
Sato M; Ando M; Minami H; Ando Y; Ando M; Yamamoto M; Sakai S; Watanabe A; Ikeda T; Sekido Y; Saka H; Shimokata K; Hasegawa Y
Cancer Chemother Pharmacol; 2001 Dec; 48(6):481-7. PubMed ID: 11800029
[TBL] [Abstract][Full Text] [Related]
15. A phase I study of irinotecan administered on a weekly schedule in pediatric patients.
Bomgaars L; Kerr J; Berg S; Kuttesch J; Klenke R; Blaney SM
Pediatr Blood Cancer; 2006 Jan; 46(1):50-5. PubMed ID: 15768380
[TBL] [Abstract][Full Text] [Related]
16. Phase I trial of temozolomide and protracted irinotecan in pediatric patients with refractory solid tumors.
Wagner LM; Crews KR; Iacono LC; Houghton PJ; Fuller CE; McCarville MB; Goldsby RE; Albritton K; Stewart CF; Santana VM
Clin Cancer Res; 2004 Feb; 10(3):840-8. PubMed ID: 14871959
[TBL] [Abstract][Full Text] [Related]
17. Phase I and pharmacokinetic study of irinotecan (CPT-11) administered daily for three consecutive days every three weeks in patients with advanced solid tumors.
Catimel G; Chabot GG; Guastalla JP; Dumortier A; Cote C; Engel C; Gouyette A; Mathieu-Boué A; Mahjoubi M; Clavel M
Ann Oncol; 1995 Feb; 6(2):133-40. PubMed ID: 7786821
[TBL] [Abstract][Full Text] [Related]
18. Phase I and pharmacokinetic study of UCN-01 in combination with irinotecan in patients with solid tumors.
Jimeno A; Rudek MA; Purcell T; Laheru DA; Messersmith WA; Dancey J; Carducci MA; Baker SD; Hidalgo M; Donehower RC
Cancer Chemother Pharmacol; 2008 Mar; 61(3):423-33. PubMed ID: 17429623
[TBL] [Abstract][Full Text] [Related]
19. A phase I and pharmacokinetic study of fixed-dose selenomethionine and irinotecan in solid tumors.
Fakih MG; Pendyala L; Smith PF; Creaven PJ; Reid ME; Badmaev V; Azrak RG; Prey JD; Lawrence D; Rustum YM
Clin Cancer Res; 2006 Feb; 12(4):1237-44. PubMed ID: 16489079
[TBL] [Abstract][Full Text] [Related]
20. Phase I and pharmacokinetic study of cetuximab and irinotecan in children with refractory solid tumors: a study of the pediatric oncology experimental therapeutic investigators' consortium.
Trippett TM; Herzog C; Whitlock JA; Wolff J; Kuttesch J; Bagatell R; Hunger SP; Boklan J; Smith AA; Arceci RJ; Katzenstein HM; Harbison C; Zhou X; Lu H; Langer C; Weber M; Gore L
J Clin Oncol; 2009 Oct; 27(30):5102-8. PubMed ID: 19770383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
